Detalhe da pesquisa
1.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644155
2.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644154
3.
Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial.
Gastroenterology
; 163(5): 1294-1305.e3, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35940251
4.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol
; 21(3): 771-788.e10, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152897
5.
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
Gastroenterology
; 163(4): 950-964, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788348
6.
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Clin Gastroenterol Hepatol
; 20(9): 2074-2082, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34843987
7.
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.
Scand J Gastroenterol
; 57(4): 439-445, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34968158
8.
Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
Clin Gastroenterol Hepatol
; 19(6): 1218-1225.e4, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445951
9.
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol
; 19(5): 947-954.e2, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32360982
10.
High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial.
Clin Gastroenterol Hepatol
; 19(8): 1573-1582.e5, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461138
11.
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Gastroenterology
; 159(1): 139-147, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32224129
12.
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
Am J Gastroenterol
; 116(1): 134-141, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33177349
13.
Artificial intelligence and its impact on quality improvement in upper and lower gastrointestinal endoscopy.
Dig Endosc
; 33(2): 242-253, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145847
14.
Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density.
Gut
; 69(10): 1778-1786, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31915237
15.
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
Gut
; 69(4): 658-664, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285357
16.
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease.
Clin Gastroenterol Hepatol
; 18(9): 2139-2141.e2, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31473359
17.
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
Clin Gastroenterol Hepatol
; 18(3): 637-646.e11, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31128336
18.
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Gastroenterology
; 157(4): 997-1006.e6, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175865
19.
Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease.
Clin Gastroenterol Hepatol
; 18(8): 1704-1718, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31881273
20.
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
Gastroenterology
; 154(5): 1343-1351.e1, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29317275